Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) Director Ra Capital Management, L.P. acquired 479,039 shares of the stock in a transaction that occurred on Tuesday, June 9th. The stock was purchased at an average price of $6.91 per share, for a total transaction of $3,310,159.49. Following the completion of the acquisition, the director owned 15,683,034 shares in the company, valued at $108,369,764.94. The trade was a 3.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $7.91 per share, with a total value of $4,339,267.80.
- On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $7.00 per share, with a total value of $721.00.
- On Monday, May 11th, Ra Capital Management, L.P. acquired 6,510,416 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $11.52 per share, for a total transaction of $74,999,992.32.
Artiva Biotherapeutics Price Performance
NASDAQ ARTV opened at $8.00 on Friday. Artiva Biotherapeutics, Inc. has a 12 month low of $1.47 and a 12 month high of $14.53. The firm’s fifty day moving average price is $8.89 and its 200 day moving average price is $6.12. The company has a market capitalization of $197.76 million, a price-to-earnings ratio of -2.26 and a beta of 2.38.
Wall Street Analysts Forecast Growth
ARTV has been the topic of several research analyst reports. Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Needham & Company LLC reiterated a “buy” rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Finally, HC Wainwright lifted their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Artiva Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $39.00.
Read Our Latest Stock Report on Artiva Biotherapeutics
Institutional Investors Weigh In On Artiva Biotherapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $41,000. Bank of America Corp DE increased its stake in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after acquiring an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in Artiva Biotherapeutics in the second quarter valued at approximately $53,000. Qube Research & Technologies Ltd bought a new position in shares of Artiva Biotherapeutics in the second quarter worth about $58,000. Finally, Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics in the second quarter worth about $67,000.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
Featured Articles
- Five stocks we like better than Artiva Biotherapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
